卡博赞替尼治疗前列腺癌的进展[勘误]

Core Evidence Pub Date : 2014-05-16 DOI:10.2147/CE.S67095

U. Vaishampayan

{"title":"卡博赞替尼治疗前列腺癌的进展[勘误]","authors":"U. Vaishampayan","doi":"10.2147/CE.S67095","DOIUrl":null,"url":null,"abstract":"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Core Evidence Publish your work in this journal","PeriodicalId":10764,"journal":{"name":"Core Evidence","volume":"9 1","pages":"69 - 69"},"PeriodicalIF":0.0000,"publicationDate":"2014-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/CE.S67095","citationCount":"0","resultStr":"{\"title\":\"Development of cabozantinib for the treatment of prostate cancer [Corrigendum]\",\"authors\":\"U. Vaishampayan\",\"doi\":\"10.2147/CE.S67095\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Core Evidence Publish your work in this journal\",\"PeriodicalId\":10764,\"journal\":{\"name\":\"Core Evidence\",\"volume\":\"9 1\",\"pages\":\"69 - 69\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2147/CE.S67095\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Core Evidence\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/CE.S67095\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Core Evidence","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CE.S67095","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

许可证。许可的完整条款可在http://creativecommons.org/licenses/by-nc/3.0/上获得。允许非商业用途的工作，没有任何进一步的许可，从多芬医学出版社有限公司，只要工作适当署名。超出许可范围的许可由多芬医疗新闻有限公司管理。有关如何请求许可的信息可在以下网址找到:http://www.dovepress.com/permissions.php核心证据在本期刊中发表您的工作

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]

License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Core Evidence Publish your work in this journal

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Core Evidence PHARMACOLOGY & PHARMACY-

自引率

0.00%

发文量

期刊介绍： Core Evidence evaluates the evidence underlying the potential place in therapy of drugs throughout their development lifecycle from preclinical to postlaunch. The focus of each review is to evaluate the case for a new drug or class in outcome terms in specific indications and patient groups The emerging evidence on new drugs is reviewed at key stages of development and evaluated against unmet needs